Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate - Wikidata - thesis-toulmin - TriplyDB

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

http://www.wikidata.org/entity/Q28178563

about

Progesterone acts via the nuclear glucocorticoid receptor to suppress IL-1β-induced COX-2 expression in human term myometrial cells Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study Prenatal administration of progestogens for preventing preterm birth in women with a multiple pregnancy Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy Progestational agents for treating threatened or established preterm labour Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth Progestational agents for treating threatened or established preterm labour Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy Prophylactic oral betamimetics for preventing preterm birth in women with a twin pregnancy Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial Preterm prediction study: comparison of the cervical score and Bishop score for prediction of spontaneous preterm delivery Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro Immunology of term and preterm labor Inflammatory aetiology of human myometrial activation tested using directed graphs Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition Mechanical signaling in reproductive tissues: mechanisms and importance Progesterone to prevent spontaneous preterm birth Use of progesterone and progestin analogs for inhibition of preterm birth and other uterine contractility disorders The uterine myocyte as a target for prevention of preterm birth Perinatal neuroprotection update Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations Prevention of preterm delivery: current challenges and future prospects Bridging progestogens in pregnancy and pregnancy prevention Recent advances in the prevention and management of preterm birth Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins Progesterone modulates integrin {alpha}2 (ITGA2) and {alpha}11 (ITGA11) in the pregnant cervix Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice Lessons learned from the Philadelphia Collaborative Preterm Prevention Project: the prevalence of risk factors and program participation rates among women in the intervention group Cerebral Palsy-Trends in Epidemiology and Recent Development in Prenatal Mechanisms of Disease, Treatment, and Prevention Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Maternal Marijuana Use, Adverse Pregnancy Outcomes and Neonatal Morbidity.Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.Single nucleotide polymorphisms in the human progesterone receptor gene and spontaneous preterm birth.

P2860

Q21090836-24A0A748-B57C-4B0D-982A-C58E641FF774 Q21144640-F4DB7570-8A6C-406E-9ABD-211C016AC061 Q24186836-118968BA-93C4-402D-A414-8F4EB34DCE2B Q24193685-86FDE405-22E8-4F19-BA6E-EB7954B1F61B Q24200505-BC530B54-1CA9-4A76-9C3C-ABF37B45CB31 Q24200651-1BC4760D-E517-435E-8ACA-AE972A47C7DE Q24200891-5E3456DF-36A5-4EE9-BD5D-1BEBD3D27B6F Q24200953-561F2780-1E31-4E10-A0ED-0C4DEEE24B70 Q24240588-5CD92C7A-8EC2-49AA-8D7C-1CA324CA69FD Q24242855-A6821C7C-4789-408F-80E4-1B2B30FEE9B4 Q24244821-867F9B25-3310-4B7C-9692-9F5ADB5DD69A Q24246616-188712C0-4797-41AD-8713-0A51B59F1C64 Q24247273-B7D02D0D-E506-4BED-A8FF-3816025517F8 Q24622553-33FF541B-E64A-4025-B398-0FC478A548B9 Q24650831-8890938D-77A6-4782-BED1-1AC082B87888 Q24791673-A821855E-6903-4205-9F70-2B1510021468 Q24801342-0EF6B0DC-2064-47F4-929C-C1E9870E63C2 Q24813232-3F8A01CD-8B1B-4062-9317-4966C6BC568A Q26745938-21D77F4B-E836-486C-9C34-5396490B1FE6 Q26822613-0EAE8ADD-0A55-463F-92C2-0733EAC25187 Q26827262-F290F79D-3DF6-483A-B445-8CE35C258D72 Q26862855-72055D13-8193-485E-948F-EB74077097C9 Q26864122-536871BC-5B41-4C43-81F0-2A9EC16FE0DC Q26970812-D69036F1-2B0F-4990-A456-38DD2CC66123 Q27024142-602E4615-51F9-4E62-AEB3-B1909200661B Q28078230-04B1F485-2818-40CE-93F0-CF9D168FA77A Q28082015-BFF97FE3-69E8-45AE-9B8D-7E424C95CD14 Q28087299-FAA44580-70F6-4C40-8DB9-C283BFAF463F Q28260077-CF020A99-2C26-4B97-8FCA-F0D67282B14A Q28580517-AA67D7A2-29C5-4D4C-996B-498CCC2BB7E3 Q28654984-53DE06E8-362B-40AB-953A-13AA0450C778 Q29109904-1ADE930B-FF92-485C-B300-71B44529CCF5 Q30235534-DD1E7154-580A-46C6-9F60-0DBFFBB72AE5 Q30244368-4C8DD5BC-23AE-425A-BD4C-C371C6103CC2 Q30252214-7A9E58D9-A81B-4563-81F1-CAD1680E085C Q30702434-ADF9F582-DAAB-4960-AB75-238B025900B9 Q30844080-42764EE5-8852-4653-9A12-AE18AE5AD626 Q31031937-399BE7FB-3A6E-4F8E-9764-63FDA878299D Q33288186-D43891C6-1800-409E-AFF7-35B9308888C8 Q33319951-E36624DA-9E2B-41F6-B91E-6186BCE79F78

P2860

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

http://www.wikidata.org/entity/Q28178563

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@ast

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@en

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@nl

type

label

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@ast

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@en

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@nl

prefLabel

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@ast

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@en

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@nl

P1433

Q28178563-8A6946E0-BE2A-41A4-8F55-6630D4B3E1C9

P1476

Q28178563-C6F84708-657E-407D-995B-13071D55F8B7

P2093

Q28178563-04760DEC-9370-428A-B3ED-E0406BCF2E45

Q28178563-0E6464DA-0E71-4986-8DA4-CDE81CD40898

Q28178563-1DA9A885-68E9-4BC8-809D-DE8DD21E60F2

Q28178563-467A744A-63F6-41C2-A6EB-2E0B0F521C15

Q28178563-4CDF8CE6-5A73-4F89-A1AC-36B9CFC44A05

Q28178563-5146EA3D-F041-496F-960C-5ADB908A29D7

Q28178563-57E3CC5B-403C-4B2A-B05C-41C01D7BF67D

Q28178563-5CC02DDF-7C0E-4D59-83A8-BBBDFACF2E7A

Q28178563-5D8DF662-5620-4406-8B8D-FB0DB924CC04

Q28178563-6269F026-D10B-49AD-9B89-7B8536493989

P304

Q28178563-55F60880-F006-4C87-87AB-8371C12E82D4

P31

Q28178563-82142B89-7A69-4835-8464-349461EFF441

P3181

Q28178563-46B0F9B8-1B50-47B4-AB9A-225FBBC55EBC

P356

Q28178563-55D54A21-3FC8-44A8-803A-04565328E20C

P407

Q28178563-5093C079-4FAA-4F17-BF55-F26A9A73B2B4

P433

Q28178563-1484B201-6504-4F36-93E6-A8FC276C089F

P478

Q28178563-BE60C8BF-2D89-4697-9BA9-8DDB713003E5

P50

Q28178563-5322A7F9-2109-46EA-8F38-FFED5E3B50F0

Q28178563-C9314C0B-16C6-48C3-ABAF-12666275EC64

Q28178563-E2DCD972-58C0-4630-BAB4-370C9D126CA3

Q28178563-E9AA80CC-6F4A-4049-9063-36AC2E2009C6

P577

Q28178563-FC4C49DB-9551-4EB1-A15F-B119A3533A14

P698

Q28178563-45EE1C47-70BE-4AD1-A384-688E93527A72

P3181

P356

P1433

The New England Journal of Medicine

P1476

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate

@en

P2093

Atef H Moawad

http://www.w3.org/2001/XMLSchema#string

Baha Sibai

http://www.w3.org/2001/XMLSchema#string

Brian Mercer

http://www.w3.org/2001/XMLSchema#string

Deborah Conway

http://www.w3.org/2001/XMLSchema#string

Elizabeth Thom

http://www.w3.org/2001/XMLSchema#string

Jay D Iams

http://www.w3.org/2001/XMLSchema#string

John C Hauth

http://www.w3.org/2001/XMLSchema#string

John M Thorp

http://www.w3.org/2001/XMLSchema#string

Kenneth J Leveno

http://www.w3.org/2001/XMLSchema#string

Mark Klebanoff

http://www.w3.org/2001/XMLSchema#string

P304

2379-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

585283

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA035140

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

348

http://www.w3.org/2001/XMLSchema#string

P50

Alan M. Peaceman

Michael W. Varner

Steve N Caritis

Catherine Y Spong

P577

2003-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12802023

http://www.w3.org/2001/XMLSchema#string